Home > Haematology > ASH 2021 Focus on CAR T-Cell Therapy

ASH 2021 Focus on CAR T-Cell Therapy


American Society of Hematology Atlanta, 11–14 December 2021

Table of Contents



Welcome to our Focus Edition on CAR T-cell therapy news

ASH 2021 Focus on CAR T-Cell Therapy Podcast

Presented By
Dr Rachel Giles, Medicom

Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma

Expert
Dr Frederick Locke, Moffitt Cancer Cancer, Tampa, Florida, USA

CAR T-cell Therapy

Most re-hospitalisations within first month from CAR T-cell infusion

Expert
Dr Kelly Kenzik, Institute for Cancer Outcomes and Survivorship, University of Alabama, USA

CD22-directed CAR T-cell therapy safe and well-tolerated in R/R LBCL

Expert
Dr Matthew J. Frank, Stanford University School of Medicine, USA

High rate of rapid and complete responses with axi-cel in high-risk large B-cell lymphoma

Expert
Dr Sattva S. Neelapu, MD Anderson Cancer Center, Houston, USA

Novel anti-CD19 plus lenalidomide prolonged survival in R/R DLBCL

Expert
Dr Grzegorz Nowakowski, Mayo Clinic, Rochester, USA

Liso-cel superior to standard-of-care as second-line therapy in large B-cell lymphoma

Expert
Dr Manali Kamdar, University of Colorado Cancer Center, Denver, USA

CIRS is predictive of outcomes in CAR T-cell recipients with R/R DLBCL

Expert
Dr Geoffrey Shouse, City of Hope Comprehensive Cancer Center, USA

Axi-cel more effective but tisa-cel less toxic in large B-cell lymphoma

Expert
Dr Emmanuel Bachy, Hospices Civils de Lyon, France

Axi-cel improved event-free survival in relapsed/refractory large B-cell lymphoma

Expert
Dr Frederick Locke, Moffitt Cancer Cancer, Tampa, Florida, USA

Comparable outcomes with second-line tisa-cel versus standard-of-care for relapsed/refractory aggressive NHL

Expert
Dr Michael R. Bishop, David and Etta Jonas Center for Cellular Therapy, University of Chicago, USA

Improved QoL with axi-cel versus standard-of-care in R/R LBCL

Expert
Dr Mahmoud Elsawy, Dalhousie University, Halifax, USA
site created by:   

© 2024 Medicom Medical Publishers.  All rights reserved. Terms and Conditions | Privacy Policy



HEAD OFFICE
Laarderhoogtweg 25
1101 EB Amsterdam
The Netherlands
T: +31 85 4012 560
E: publishers@medicom-publishers.com